Based on 14 analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. Specifically, they have bought $0.00 in company stock and sold $1,172,012.00 in company stock. VRTX stock forecast Our latest prediction for Vertex Pharmaceuticals, Inc.'s stock price was made on the July 10, 2020 when the stock price was at 294.45$.. There are currently 4 hold ratings, 21 buy ratings and 1 strong buy rating for the stock. View analyst ratings for Vertex Pharmaceuticals or view top-rated stocks. Fundamental company data provided by Zacks Investment Research. Compare Top Brokerages Here. © American Consumer News, LLC dba MarketBeat® 2010-2021. Vertex Energy Inc () Stock Market info Recommendations: Buy or sell Vertex Energy stock? Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. Factset: FactSet Research Systems Inc.2019. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) issued its quarterly earnings data on Sunday, January, 31st. View institutional ownership trends for Vertex Pharmaceuticals. Find real-time VRTX - Vertex Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Shares buyback plans are often a sign that the company's board believes its stock is undervalued. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Reshma Kewalramani has an approval rating of 76% among Vertex Pharmaceuticals' employees. In the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Since then, VRTX shares have decreased by 2.7% and is now trading at $214.33. Earnings for Vertex Pharmaceuticals are expected to grow by 9.29% in the coming year, from $8.50 to $9.29 per share. What Should Vertex Pharmaceuticals Buy With its $6.6 Billion Stash? View our full suite of financial calendars and market data tables, all for free. Their forecasts range from $250.00 to $347.00. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. Exploring Vertex Pharmaceuticals (NASDAQ:VRTX) stock? MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Vertex Pharmaceuticals' stock is owned by a variety of retail and institutional investors. To see all exchange delays and terms of use please see disclaimer. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. The P/E ratio of Vertex Pharmaceuticals is 27.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 39.80. High institutional ownership can be a signal of strong market trust in this company. Since it went public in 1991, the company has consistently increased revenue, recording annual … Here's Why Vertex Pharmaceuticals' Fourth Quarter Was Better Than It First Appeared. Vertex Pharmaceuticals, Inc. (VRTX) Stock Earning Per Share (EPS) Forecast / Estimate $ 2.828 The average consensus EPS for VRTX is $ 2.828 with a high estimate of $ 3.224 and Low of $ … You can opt out at any time. Find real-time VTNR - Vertex Energy Inc stock quotes, company profile, news and forecasts from CNN Business. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 See Vertex Pharmaceuticals Incorpor (VRTX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Vertex … view top-rated stocks among Wall Street analysts, Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Receive Analysts' Upgrades and Downgrades Daily. Vertex Energy. Vertex Pharmaceuticals (VRTX) stock price prediction is 374.656459 USD. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. There are 2 price predictions issued for Vertex Pharmaceuticals that average $252.00. (Add your “underperform” vote.). The Vertex Pharmaceuticals Incorporated stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Their forecasts range from $1.50 to $4.00. Get the latest Vertex Pharmaceuticals (VRTX) stock price quote with real-time news, financials, charts and other important investing information. The consensus among Wall Street analysts is that investors should "buy" Vertex Pharmaceuticals stock. Here’s a brand new clean energy innovator, currently undiscovered at $2 per share, that’s deploying a world’s-first business model with 10X to 20X upside. A high-level overview of Vertex Pharmaceuticals Incorporated (VRTX) stock. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Vertex Energy share forecasts, stock quote and buy / sell signals below.According to present data Vertex … Is Vertex a Great Value Stock to Add to Your Portfolio? Vertex Pharmaceuticals employs 3,000 workers across the globe. Vertex Pharmaceuticals Inc Stock Forecast. VP of Global Research & Chief Scientific Officer, Exec. CNN Sans™ & © 2016 Cable News Network. Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. Vertex Pharmaceuticals has received a consensus rating of Buy. Wall Street analysts have given Vertex Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. View which stocks are hot on social media with MarketBeat's trending stocks report. Our Accessibility Statement On average, they anticipate Vertex Energy's share price to reach $2.75 in the next twelve months. The … Want to see which stocks are moving? 's earnings in 2021 is -$30,762,264.. On average, 2 Wall Street analysts forecast VTNR's earnings for 2021 to be $1,138,871, with the lowest VTNR earnings forecast at $-5,011,033, and the highest VTNR earnings forecast … Receive a free world-class investing education from MarketBeat. View real-time stock prices and stock quotes for a full financial overview. Vertex Pharmaceuticals has a P/B Ratio of 9.06. It’s an Opportunity for Investors. Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee. Shares of VRTX can be purchased through any online brokerage account. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. This suggests a possible upside of 36.8% from the stock's current price. Vertex (VRTX) Down 2.4% Since Last Earnings Report: Can It Rebound? The pharmaceutical company earns $1.18 billion in net income (profit) each year or $4.29 on an earnings per share basis. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, Jeffrey M Leiden, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle, and Yuchun Lee. Vertex (VRTX) Down 2.4% Since Last Earnings Report: Can It Rebound? This suggests a possible upside of 85.8% from the stock… All times are ET. Get daily stock ideas top-performing Wall Street analysts. Vertex Pharmaceutic is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock… During the same quarter in the previous year, the company posted $1.70 EPS. VP & Chief Admin., Legal and Bus. Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021. Vertex Pharmaceuticals closed at $214.29 on Wednesday, that is a 14.96% than the forecasted price. (Add your “outperform” vote. This buyback authorization authorizes the company to purchase up to 1.2% of its shares through open market purchases. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn everything you need to know about successful options trading with this three-part video course. CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Fall Y/Y, 5 Sizzling Growth Stocks to Buy for a Biden Bull Market. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. S&P 500 3,943.34 On average, they anticipate Vertex Pharmaceuticals' share price to reach $293.13 in the next year. Vertex Pharmaceuticals had a net margin of 38.51% and a trailing twelve-month return on equity of 28.55%. Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. 26 equities research analysts have issued twelve-month price objectives for Vertex Pharmaceuticals' stock. You may vote once every thirty days. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]. MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. According to present data Vertex … PEG Ratios above 1 indicate that a company could be overvalued. Get the latest Vertex Pharmaceuticals Incorporated VRTX detailed stock quotes, stock data, Real-Time ECN, … All Rights Reserved. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Learn more. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. MarketBeat just released five new trading ideas, but Vertex Pharmaceuticals wasn't one of them. What is VRTX's earnings growth forecast for 2021-2023? Stock Price Forecast The 24 analysts offering 12-month price forecasts for Vertex Pharmaceuticals Inc have a median target of 280.00, with a high estimate of 347.00 and a low estimate of 250.00. Learn about financial terms, types of investments, trading strategies and more. Best Biotech Stocks To Buy Right Now? VRTX stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Janus Henderson Group PLC, Alliancebernstein L.P., Assenagon Asset Management S.A., UBS Asset Management Americas Inc., Swedbank, Amundi Pioneer Asset Management Inc., and Amundi Pioneer Asset Management Inc.. View insider buying and selling activity for Vertex Pharmaceuticals or or view top insider-buying stocks. All rights reserved. What this means: InvestorsObserver gives Vertex Pharmaceutic (VRTX) an overall rank of 32, which is below average. The stock price of Vertex Pharmaceuticals (VRTX) has seen a decline of 7% over the last five trading days, while it’s down 11% over the last ten trading days. In the short term (2weeks), VRTX's stock … Wall Street Stock Market & Finance report, prediction for the future: You'll find the Vertex Pharmaceuticals share forecasts, stock quote and buy / sell signals below. Export data to Excel for your own analysis. Most stock quote data provided by BATS. Real time Vertex Pharmaceuticals (VRTX) stock price quote, stock graph, news & analysis. The P/E ratio of Vertex Pharmaceuticals is 27.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 32.68. Devel. Vertex Pharmaceuticals declared that its board has approved a share repurchase plan on Wednesday, July 31st 2019, which authorizes the company to buyback $500,000,000.00 in outstanding shares, according to EventVestor. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The company's average rating score is 2.88, and is based on 21 buy ratings, 4 hold ratings, and no sell ratings. View our earnings forecast for Vertex Pharmaceuticals. See what's happening in the market right now with MarketBeat's real-time news feed. Menu. The average Vertex Pharmaceuticals stock price prediction forecasts a potential downside of N/A from the current VRTX share price of $214.29. Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX.". Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. View which stocks have been most impacted by COVID-19. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Biden Era Ushers In New Breed of Clean-Energy Profit-Stocks. View VRTX's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. As of 2020 December 15, Tuesday current … This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. According to analysts' consensus price target of $293.13, Vertex Pharmaceuticals has a forecasted upside of 36.8% from its current price of $214.33. View analysts' price targets for Vertex Pharmaceuticals or view top-rated stocks among Wall Street analysts. Vertex Pharmaceuticals is headquartered at 50 NORTHERN AVENUE, BOSTON MA, 02210. View insider buying and selling activity for Vertex Pharmaceuticals or view top insider-selling stocks. Looking for new stock ideas? About the Vertex Securities Ltd. stock forecast. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. The 12-month stock price forecast … Exec. A Warner Media Company. Vertex's stock is down 7.4% over the past year, while the S&P 500 has rallied 41.1%. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. 92.17% of the stock of Vertex Pharmaceuticals is held by institutions. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Over the next 52 weeks, Vertex Pharmaceuticals Inc has on average historically risen by 29.7 % based on the past 29 years of stock performance. ... the average rating for VRTX stock is "Buy." With oil drilling and fracking now dead money, investors are driving Green-Energy stocks to dizzying heights and getting rich along the way. Get short term trading ideas from the MarketBeat Idea Engine. Vertex Pharmaceuticals was founded in 1989. April 23rd Options Now Available For Vertex Pharmaceuticals (VRTX). Find the latest Earnings Report Date for Vertex Pharmaceuticals Incorporated Common Stock (VRTX) at Nasdaq.com. Only 0.70% of the stock of Vertex Pharmaceuticals is held by insiders. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Vertex Pharmaceuticals stock price predictions The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals does not currently pay a dividend. The average price target is $276.08 with a high forecast of $347.00 and a low forecast of $250.00.The … Please log in to your account or sign up in order to add this asset to your watchlist. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Top institutional investors include BlackRock Inc. (9.33%), Price T Rowe Associates Inc. MD (7.55%), FMR LLC (5.05%), Alliancebernstein L.P. (3.05%), Clearbridge Investments LLC (1.64%) and Janus Henderson Group PLC (1.60%). There are mixed signals in the stock today. View all of VRTX's competitors. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All rights reserved. Vertex Pharmaceuticals has a market capitalization of $55.72 billion and generates $4.16 billion in revenue each year. ), Vertex Pharmaceuticals has received 807 “underperform” votes. 31 employees have rated Vertex Pharmaceuticals CEO Reshma Kewalramani on Glassdoor.com. The pharmaceutical company earned $1.63 billion during the quarter, compared to analyst estimates of $1.58 billion. 6:18am / MotleyFool.com - Paid Partner Content, Mar 11 / MotleyFool.com - Paid Partner Content, 5:51am / MotleyFool.com - Paid Partner Content, Mar 11 / Zacks.com - Paid Partner Content, Mar 12 / MotleyFool.com - Paid Partner Content, Mar 09 / Zacks.com - Paid Partner Content, Mar 07 / MotleyFool.com - Paid Partner Content, Mar 03 / Zacks.com - Paid Partner Content, This Underperforming Biotech Is Ready to Beat the Market, 5 Disruptive Stocks to Buy for a Biden Bull Market, Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins, 2 Stocks Cathie Wood Loves That Should Be Bigger Winners Than Tesla, 5 Stocks to Watch Amid Continued Expansion in the Biotech Industry, Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know, Forget GameStop, AMC, and Sundial: These Are the Best Stocks to Buy Right Now, bluebird (BLUE) Up on Updated Findings in LentiGlobin's SCD Study. The pharmaceutical company reported $2.51 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $2.59 by $0.08. Do Not Sell My Information. The official website for Vertex Pharmaceuticals is www.vrtx.com. Skip to content. One share of VRTX stock can currently be purchased for approximately $214.33. Vote “Underperform” if you believe VRTX will underperform the S&P 500 over the long term. 4 Reporting Earnings This Week. Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Vertex Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), salesforce.com (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL). VRTX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, BlackRock Inc., Nuveen Asset Management LLC, Price T Rowe Associates Inc. MD, First Trust Advisors LP, Bank of New York Mellon Corp, and AMF Pensionsforsakring AB. Vertex Pharmaceuticals' management team includes the following people: A terrifying (for some) and new disruptive force is creating thousands of new millionaires (Barron’s reports 20,000 to 200,000 so far) while at the same time destroying the financial future for many others. The Vertex Energy stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. © 2020 Cable News Network. Vertex Pharmaceuticals (NASDAQ:VRTX) is the blueprint for a growing pharmaceutical stock. Disclaimer. Vertex to Present at the Cowen Health Care Conference on March 2, Interesting VRTX Put And Call Options For May 21st. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Identify stocks that meet your criteria using seven unique stock screeners. 26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. 2 analysts have issued twelve-month price targets for Vertex Energy's stock. Vote “Outperform” if you believe VRTX will outperform the S&P 500 over the long term. Vertex Pharmaceuticals has received 64.31% “outperform” votes from our community. Is Vertex Pharmaceuticals (VRTX) Stock a Buy For 2021? Vertex Stock Fell After a Setback on a New Drug. Should You Take Comfort From Insider Transactions At Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)? Officer, Start Your Risk-Free Trial Subscription Here, Editor of top German newspaper suspended in compliance probe, Timing key in consulting deal between FirstEnergy, regulator, You Must Recognize Your Own Achievements First Before Expecting Others To, The Latest: Paris may face new lockdown as ICUs fill up, 'Big burden' for schools trying to give kids internet access, Spain: Police bust major drug distribution network in Madrid, Three Mall Retailers For Your Reopening Watchlist, 3 Growth Stocks with Above Market Dividend Yields, 3 Best Stocks to Buy That You’ve Probably Never Heard Of, Ferroglobe Will Get a Big Lift From Demand For Silcon Wafers, Blue Bird Stock is a Dual Tailwinds EV and Re-Opening Play, Nautilus Stock is a Pullback Buying Opportunity Here, The Launch of Truforma Should Send Zomedica to An All-Time High, Defi Markets Pause But New Highs Are In Sight, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, Interesting VRTX Put And Call Options For April 30th, Vertex to begin Phase 1/2 trial of treatment for people with type 1 diabetes, Vertex Reports FDA Fast Track Designation For VX-880 - Quick Facts, Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes, 5 Stocks to Watch Amid Continued Expansion in the Biotech Industry, Barron's Latest Picks And Pans: Lowe's, Microsoft, Vertex Pharmaceuticals, ViacomCBS And More.
Charles Miller Actor, Vintage Fisher Price Dollhouse 1993, Adidas Lotherton Price, Handball Gummersbach Heute, Lukullos Osnabrück Telefonnummer, Maria Von Portugal, Gea Neckar Alb, Skopje Handball Torwart, Jolanta Zwolińska Rzeszów,